Although these data suggest that the efficacy of linagliptin in the heart is mediated by suppression of TRAF3IP2 expression and downstream inflammatory signaling, we have not demonstrated a direct role for TRAF3IP2 in WD-induced DD. Here, TRAF3IP2 is linked to Wilson disease.